ClinicalTrials.gg
CompletedNCT02065700DARWIN3Updated Jun 4, 2024Results posted

Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

A Phase 2 interventional study of Filgotinib in Rheumatoid Arthritis, sponsored by Galapagos NV. Completed at 111 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
739
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
4th of 17
739 · median 287
Started
2014
the only one that year
Phase 2
6 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
6 of 17
Galapagos NV

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 2, and was the 5th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of the study was to evaluate the long-term safety and tolerability of filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.

Participants were enrolled in this open-label long-term follow-up study after they had completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) (NCT01888874) or GLPG0634-CL-204 (DARWIN2) (NCT01894516), and were evaluated for any side effects that might have occured (long-term safety and tolerability) when taking filgotinib. During the course of the study, participants were also examined for long-term effects of filgotinib administration on disease activity (efficacy), participant's disability, fatigue, and quality of life.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Methotrexate
  • insufficient responders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants who completed one of the qualifying core studies GLPG0634-CL-203 or GLPG0634-CL-204 and may benefit from filgotinib long-term treatment according to the Investigator's judgment
  • Females of and sexually active men must agree to use highly effective method of as specified in the protocol, during the study and for at least 12 weeks after the last dose of filgotinib

Key Exclusion Criteria:

  • Participants who prematurely withdrew from one of the 2 core studies (GLPG0634-CL-203 or GLPG0634-CL-204), for any reason
  • Persistent abnormal lab values during one of the 2 core studies (GLPG0634-CL-203 or GLPG0634-CL-204), according to the Investigator's judgment
  • Diagnosis of rheumatic disease or inflammatory joint disease other than rheumatoid arthritis, except for secondary Sjogren's syndrome
  • Any condition or circumstances which, in the opinion of the Investigator, may make a participant unlikely or unable to complete the study or comply with study procedures and requirements

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
739 participants (actual)

Study arms

  • Experimental
    Filgotinib Darwin 1

    Participants in Study GLPG0634-CL-203 (NCT01888874) were rolled-over to receive an oral dose of filgotinib at a daily dose of 200 milligrams (mg) in this extension study, with the exception of male participants in the United States (US) who were limited to a daily dose of 100 mg due to a Food and Drug Administration (FDA) requirement based on a non-clinical finding. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval. In case of intolerance or for safety reasons, and as per investigator's discretion, a daily dose of filgotinib 200 mg could be decreased to 100 mg per day, and later returned to 200 mg per day after the reasons for decreasing the dose were resolved.

    Drug: Filgotinib

  • Experimental
    Filgotinib Darwin 2

    Participants from Study GLPG0634-CL-204 (NCT01894516) were rolled-over to receive oral dose of filgotinib tablet at 200 mg once daily (q.d) in this extension study. Treatment was administered until marketing, local (if applicable) regulatory and/or pertinent local reimbursement approval. Participants started the study with the same dose level (filgotinib 200 mg per day) and in case of intolerance or safety reasons and as per investigator's discretion, the daily dose of filgotinib was decreased to 100 mg q.d and was returned to 200 mg per day after the reasons for decreasing the dose had resolved and at the investigator's discretion.

    Drug: Filgotinib

Interventions

  • Administered as Oral Tablets

    Also known as: GS-6034, GLPG0634

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Treatment-Emergent Adverse Events

    An Adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Treatment-emergent adverse events (TEAEs) were defined as any AEs with an onset date on or after the filgotinib start date in the core studies or GLPG0634-CL-205 (NCT02065700), and no later than 30 days after permanent discontinuation of filgotinib in GLPG0634-CL-205 (NCT02065700) or of either 30 days after the last dose date.

    Time frame: From First dose to Week 437

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response: Non-Responder Imputation (NRI)

    The American College of Rheumatology (ACR) response was a measurement of improvement in multiple disease assessment criteria. The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in swollen joint count 66 (SJC66), and 2) ≥ 20% improvement from baseline in tender joint count 68 (TJC68), and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2.Subject's Global Assessment of Disease Activity (SGA) (VAS), 3. Physician's Global Assessment of Disease Activity (PGA) (VAS), 4. Total HAQ-DI score, and 5. High-Sensitivity C- Reactive Protein (hsCRP).

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  2. Percentage of Participants Achieving ACR20 Response: Observed Case (OC)

    The ACR response was a measurement of improvement in multiple disease assessment criteria. The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  3. Percentage of Participants Achieving ACR50 Response: NRI

    The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  4. Percentage of Participants Achieving ACR50 Response: OC

    The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  5. Percentage of Participants Achieving ACR70 Response: NRI

    The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  6. Percentage of Participants Achieving ACR70 Response: OC

    The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5.hsCRP.

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  7. ACR N% Improvement (ACR-N) Response: OC

    ACR-N was defined as the smallest percentage improvement from core baseline in SJC66, TJC68 and the median of the following 5 items (Pain VAS \[taken from the HAQ-DI\], 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP). It had a range between 0 and 100%.

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  8. Change From Core Baseline in Disease Activity Score Based on 28 Joints Using C-reactive Protein (DAS28[CRP]): OC

    The DAS28(CRP) was a measure of the participant's disease activity calculated using the TJC (28 joints), SJC (28 joints), SGA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\] and hsCRP using the formula: DAS28(CRP) = 0.56 \* Square root \[SQRT\] (TJC28) + 0.28 \* SQRT(SJC28) + 0.36 \* Ln(CRP+1) + 0.014 \* SGA + 0.96 and the total possible score ranged from 1 to 9.4. Higher values indicated higher disease activity. A negative change from baseline indicated improvement.

    Time frame: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  9. Change From Core Baseline in Simple Disease Activity Index (SDAI): OC

    SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm), CRP (mg/dL). SDAI = TJC + SJC + SGA + PGA+ CRP. The SDAI score ranged from 0 to approximately 86. Higher SDAI indicated greater disease activity. A negative change from baseline indicated improvement.

    Time frame: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  10. Change From Core Baseline in Clinical Disease Activity Index (CDAI): OC

    The CDAI was the SDAI modified that excluded CRP and consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm). SDAI = TJC + SJC + SGA+ PGA. The CDAI score ranged from 0 to approximately 76. Higher CDAI indicated greater disease activity. A negative change from baseline indicated improvement.

    Time frame: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  11. Percentage of Participants Achieving European League Against Rheumatism (EULAR) Response: OC

    DAS28(CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None= Actual DAS28(CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28(CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28(CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28(CRP) from baseline \> 1.2, or Actual DAS28(CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28(CRP) from baseline \> 0.6 to ≤ 1.2; Good= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline \> 1.2.

    Time frame: Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  12. Percentage of Participants Achieving ACR/EULAR Remission: NRI

    A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  13. Percentage of Participants Achieving ACR/EULAR Remission: OC

    A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.

    Time frame: Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408

  14. Change From Core Baseline in Physical Component Score (PCS) of Quality of Life Using the Short Form-36 (SF-36) Scores: OC

    The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components: * Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items). * Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items). These scales were from 0 to 100 with higher scores indicating a better quality of life.

    Time frame: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384

  15. Change From Core Baseline in MCS of Quality of Life Using the SF-36 Scores: OC

    The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components: * Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items). * Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items). These scales were from 0 to 100 with higher scores indicating a better quality of life.

    Time frame: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384

  16. Change From Core Baseline in Quality of Life Using Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale: OC

    FACIT-Fatigue scale was a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). Negatively stated items were reversed by subtracting the response from "4" before being added to obtain a total score. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating less fatigue. A positive change from baseline indicated better quality of life.

    Time frame: Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384

07

Results

Posted Jun 4, 2024

Participant flow

Participants with moderately to severely active rheumatoid arthritis were enrolled in this study.

Participant flow — Overall Study
MilestoneFilgotinib Darwin 1Filgotinib Darwin 2
Started497242
Male us participants70
Completed16181
Not completed336161
Withdrew: Adverse event165101
Withdrew: Withdrawal by subject9029
Withdrew: Lost to follow-up129
Withdrew: Physician decision20
Withdrew: Sponsor request3815
Withdrew: Treatment failure32
Withdrew: Use of non-permitted concurrent therapy30
Withdrew: Adverse event and treatment failure02
Withdrew: Non-compliance with study procedures20
Withdrew: Not defined213

Outcome measures

PrimaryNumber of Participants Experiencing Treatment-Emergent Adverse Events

An Adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. Treatment-emergent adverse events (TEAEs) were defined as any AEs with an onset date on or after the filgotinib start date in the core studies or GLPG0634-CL-205 (NCT02065700), and no later than 30 days after permanent discontinuation of filgotinib in GLPG0634-CL-205 (NCT02065700) or of either 30 days after the last dose date.

Time frame:
From First dose to Week 437
Reported as:
Number · participants
Number of Participants Experiencing Treatment-Emergent Adverse Events
participantsFilgotinib Darwin 1Filgotinib Darwin 2
Number of Participants Experiencing Treatment-Emergent Adverse Events453223
SecondaryPercentage of Participants Achieving American College of Rheumatology (ACR) 20 Response: Non-Responder Imputation (NRI)

The American College of Rheumatology (ACR) response was a measurement of improvement in multiple disease assessment criteria. The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in swollen joint count 66 (SJC66), and 2) ≥ 20% improvement from baseline in tender joint count 68 (TJC68), and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain visual analog scale (VAS) (taken from the Health Assessment Questionnaire - Disability Index \[HAQ-DI\]), 2.Subject's Global Assessment of Disease Activity (SGA) (VAS), 3. Physician's Global Assessment of Disease Activity (PGA) (VAS), 4. Total HAQ-DI score, and 5. High-Sensitivity C- Reactive Protein (hsCRP).

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response: Non-Responder Imputation (NRI)
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline76.577.3
Week 1283.983.1
Week 2475.377.7
Week 3675.175.2
Week 4871.871.1
Week 6067.869.4
Week 7268.462.4
Week 8465.864.5
Week 9668.261.6
Week 10861.658.3
Week 12057.759.1
Week 13259.057.4
Week 14456.357.4
Week 15650.750.4
Week 16852.347.9
Week 18052.151.7
Week 19249.748.8
Week 20448.950.8
Week 21645.750.8
Week 22847.948.3
Week 24045.543.8
Week 25242.142.1
Week 26439.440.9
Week 27639.644.2
Week 28836.638.8
Week 30035.639.7
Week 31236.836.0
Week 32436.637.2
Week 33634.635.5
Week 34833.234.7
Week 36031.431.4
Week 37230.028.9
Week 38428.027.7
Week 39626.228.5
Week 4080.40.4
SecondaryPercentage of Participants Achieving ACR20 Response: Observed Case (OC)

The ACR response was a measurement of improvement in multiple disease assessment criteria. The ACR20 response was defined as: 1) ≥ 20% improvement from baseline in SJC66, and 2) ≥ 20% improvement from baseline in tender TJC68, and 3) ≥ 20% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR20 Response: Observed Case (OC)
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline77.479.6
Week 1286.287.4
Week 2484.889.5
Week 3686.589.2
Week 4884.686.9
Week 6084.590.8
Week 7287.987.8
Week 8487.291.8
Week 9689.991.4
Week 10886.089.2
Week 12085.991.1
Week 13288.092.1
Week 14486.789.7
Week 15687.289.7
Week 16887.284.1
Week 18089.088.7
Week 19287.988.7
Week 20489.391.8
Week 21686.693.2
Week 22889.592.9
Week 24088.389.1
Week 25289.791.9
Week 26486.390.8
Week 27691.693.9
Week 28887.985.5
Week 30088.191.4
Week 31288.887.0
Week 32489.786.5
Week 33688.788.7
Week 34887.891.3
Week 36086.788.4
Week 37289.885.4
Week 38485.384.8
Week 39685.092.0
Week 40866.750.0
SecondaryPercentage of Participants Achieving ACR50 Response: NRI

The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR50 Response: NRI
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline48.545.0
Week 1260.861.2
Week 2456.760.3
Week 3658.160.3
Week 4855.953.7
Week 6053.951.2
Week 7253.347.1
Week 8452.951.7
Week 9655.547.1
Week 10849.143.8
Week 12048.743.8
Week 13247.542.1
Week 14446.943.0
Week 15642.335.1
Week 16843.934.7
Week 18042.738.8
Week 19238.437.6
Week 20437.838.4
Week 21636.035.1
Week 22838.434.7
Week 24034.233.9
Week 25232.032.6
Week 26430.633.1
Week 27629.636.0
Week 28829.833.5
Week 30029.228.9
Week 31229.026.9
Week 32430.028.1
Week 33627.425.6
Week 34827.226.4
Week 36024.524.0
Week 37223.724.4
Week 38421.321.5
Week 39619.920.7
Week 4080.40.4
SecondaryPercentage of Participants Achieving ACR50 Response: OC

The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR50 response was defined as: 1) ≥ 50% improvement from baseline in SJC66, and 2) ≥ 50% improvement from baseline in TJC68, and 3) ≥ 50% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI) 2.SGA (VAS) 3. PGA (VAS) 4. Total HAQ-DI score 5. hsCRP.

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR50 Response: OC
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline49.446.4
Week 1262.464.1
Week 2464.169.2
Week 3667.271.6
Week 4865.965.3
Week 6067.366.3
Week 7268.565.9
Week 8469.973.5
Week 9673.269.5
Week 10868.366.7
Week 12072.967.5
Week 13271.366.7
Week 14471.367.5
Week 15672.463.0
Week 16873.460.9
Week 18072.667.1
Week 19267.567.9
Week 20469.669.4
Week 21668.164.4
Week 22872.166.7
Week 24066.969.5
Week 25268.571.2
Week 26466.774.8
Week 27668.176.3
Week 28870.873.6
Week 30072.566.7
Week 31269.664.4
Week 32472.765.4
Week 33670.163.9
Week 34871.869.6
Week 36067.867.4
Week 37270.771.1
Week 38464.265.0
Week 39665.664.9
Week 40866.750.0
SecondaryPercentage of Participants Achieving ACR70 Response: NRI

The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP.

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR70 Response: NRI
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline30.023.1
Week 1236.836.4
Week 2437.839.3
Week 3640.637.2
Week 4839.436.4
Week 6036.434.3
Week 7238.030.2
Week 8436.834.3
Week 9639.628.1
Week 10835.429.8
Week 12036.031.0
Week 13232.829.3
Week 14431.628.5
Week 15626.822.3
Week 16830.824.0
Week 18030.825.6
Week 19226.625.2
Week 20426.624.8
Week 21626.423.1
Week 22827.224.4
Week 24021.521.5
Week 25221.720.7
Week 26423.122.7
Week 27621.324.8
Week 28822.124.8
Week 30022.519.8
Week 31223.119.8
Week 32421.521.1
Week 33620.317.8
Week 34819.719.0
Week 36017.716.1
Week 37216.717.4
Week 38414.914.9
Week 39614.914.5
Week 4080.40.4
SecondaryPercentage of Participants Achieving ACR70 Response: OC

The ACR response was a measurement of improvement in multiple disease assessment criteria. ACR70 response was defined as : 1) ≥ 70% improvement from baseline in SJC66, and 2) ≥ 70% improvement from baseline in TJC68, and 3) ≥ 70% improvement from baseline in at least 3 of the following 5 items: 1. Pain VAS (taken from the HAQ-DI), 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5.hsCRP.

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR70 Response: OC
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline30.323.5
Week 1237.738.1
Week 2442.745.0
Week 3646.944.6
Week 4846.644.0
Week 6045.544.6
Week 7248.742.2
Week 8448.948.5
Week 9652.541.2
Week 10849.745.3
Week 12053.847.5
Week 13248.946.4
Week 14448.344.2
Week 15645.540.0
Week 16851.542.6
Week 18052.444.0
Week 19246.645.2
Week 20449.145.1
Week 21649.442.4
Week 22850.946.8
Week 24042.143.3
Week 25246.445.5
Week 26450.751.4
Week 27648.853.1
Week 28852.454.5
Week 30055.445.7
Week 31255.347.5
Week 32452.249.0
Week 33651.844.3
Week 34851.650.0
Week 36049.244.8
Week 37249.150.0
Week 38445.445.0
Week 39649.045.5
Week 40866.750.0
SecondaryACR N% Improvement (ACR-N) Response: OC

ACR-N was defined as the smallest percentage improvement from core baseline in SJC66, TJC68 and the median of the following 5 items (Pain VAS \[taken from the HAQ-DI\], 2.SGA (VAS), 3. PGA (VAS), 4. Total HAQ-DI score, and 5. hsCRP). It had a range between 0 and 100%.

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Mean · percentage of improvement
ACR N% Improvement (ACR-N) Response: OC
percentage of improvementFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline48.1 ± 30.2946.3 ± 27.77
Week 1256.3 ± 28.4356.3 ± 27.13
Week 2457.9 ± 29.6460.8 ± 27.76
Week 3659.8 ± 29.7060.7 ± 27.95
Week 4859.6 ± 30.6958.9 ± 28.65
Week 6059.9 ± 29.9760.1 ± 28.43
Week 7261.4 ± 28.9259.0 ± 28.47
Week 8461.6 ± 29.0763.6 ± 26.74
Week 9664.8 ± 28.6161.2 ± 26.87
Week 10861.2 ± 30.2260.9 ± 28.69
Week 12063.4 ± 29.2561.1 ± 28.72
Week 13262.3 ± 29.1561.3 ± 28.52
Week 14461.7 ± 28.9960.8 ± 29.12
Week 15661.5 ± 28.0558.0 ± 27.70
Week 16862.8 ± 29.7556.9 ± 30.25
Week 18063.2 ± 28.2959.9 ± 29.79
Week 19260.4 ± 29.1561.5 ± 27.30
Week 20462.3 ± 28.6461.9 ± 26.79
Week 21661.6 ± 29.8761.4 ± 26.86
Week 22864.2 ± 27.8363.0 ± 26.45
Week 24059.8 ± 28.2260.6 ± 28.48
Week 25262.4 ± 28.7162.5 ± 26.24
Week 26463.4 ± 29.8164.4 ± 27.05
Week 27663.3 ± 28.2765.9 ± 25.42
Week 28865.1 ± 29.6863.0 ± 29.82
Week 30064.9 ± 30.1661.9 ± 27.14
Week 31264.8 ± 29.8959.9 ± 30.37
Week 32465.9 ± 27.3961.2 ± 30.98
Week 33662.7 ± 29.3559.8 ± 28.90
Week 34864.8 ± 29.2662.8 ± 28.29
Week 36062.7 ± 29.8161.2 ± 28.32
Week 37264.2 ± 28.5864.6 ± 29.43
Week 38460.0 ± 30.2762.9 ± 30.43
Week 39661.5 ± 31.3464.7 ± 28.98
Week 40865.9 ± 41.0835.4 ± 50.04
SecondaryChange From Core Baseline in Disease Activity Score Based on 28 Joints Using C-reactive Protein (DAS28[CRP]): OC

The DAS28(CRP) was a measure of the participant's disease activity calculated using the TJC (28 joints), SJC (28 joints), SGA \[using a VAS on a scale of 0 (very well) to 100 (very poor)\] and hsCRP using the formula: DAS28(CRP) = 0.56 \* Square root \[SQRT\] (TJC28) + 0.28 \* SQRT(SJC28) + 0.36 \* Ln(CRP+1) + 0.014 \* SGA + 0.96 and the total possible score ranged from 1 to 9.4. Higher values indicated higher disease activity. A negative change from baseline indicated improvement.

Time frame:
Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Mean · score on a scale
Change From Core Baseline in Disease Activity Score Based on 28 Joints Using C-reactive Protein (DAS28[CRP]): OC
score on a scaleFilgotinib Darwin 1Filgotinib Darwin 2
Change from Core Baseline at Extension Baseline-2.7 ± 1.40-2.6 ± 1.28
Change from Core Baseline at Week 12-3.1 ± 1.28-3.1 ± 1.22
Change from Core Baseline at Week 24-3.2 ± 1.29-3.2 ± 1.33
Change from Core Baseline at Week 36-3.3 ± 1.28-3.3 ± 1.22
Change from Core Baseline at Week 48-3.3 ± 1.32-3.3 ± 1.26
Change from Core Baseline at Week 60-3.3 ± 1.22-3.4 ± 1.17
Change from Core Baseline at Week 72-3.3 ± 1.23-3.4 ± 1.21
Change from Core Baseline at Week 84-3.4 ± 1.21-3.5 ± 1.09
Change from Core Baseline at Week 96-3.4 ± 1.22-3.4 ± 1.13
Change from Core Baseline at Week 108-3.4 ± 1.22-3.3 ± 1.21
Change from Core Baseline at Week 120-3.4 ± 1.20-3.5 ± 1.14
Change from Core Baseline at Week 132-3.3 ± 1.21-3.5 ± 1.26
Change from Core Baseline at Week 144-3.4 ± 1.19-3.4 ± 1.15
Change from Core Baseline at Week 156-3.4 ± 1.22-3.4 ± 1.28
Change from Core Baseline at Week 168-3.4 ± 1.27-3.4 ± 1.20
Change from Core Baseline at Week 180-3.4 ± 1.12-3.4 ± 1.21
Change from Core Baseline at Week 192-3.3 ± 1.16-3.5 ± 1.13
Change from Core Baseline at Week 204-3.4 ± 1.16-3.5 ± 1.06
Change from Core Baseline at Week 216-3.4 ± 1.16-3.5 ± 1.15
Change from Core Baseline at Week 228-3.5 ± 1.12-3.5 ± 1.09
Change from Core Baseline at Week 240-3.4 ± 1.13-3.4 ± 1.19
Change from Core Baseline at Week 252-3.5 ± 1.11-3.6 ± 1.24
Change from Core Baseline at Week 264-3.5 ± 1.19-3.6 ± 1.20
Change from Core Baseline at Week 276-3.5 ± 1.10-3.6 ± 1.17
Change from Core Baseline at Week 288-3.5 ± 1.22-3.6 ± 1.28
Change from Core Baseline at Week 300-3.6 ± 1.19-3.5 ± 1.23
Change from Core Baseline at Week 312-3.5 ± 1.27-3.4 ± 1.30
Change from Core Baseline at Week 324-3.6 ± 1.14-3.5 ± 1.24
Change from Core Baseline at Week 336-3.5 ± 1.17-3.4 ± 1.16
Change from Core Baseline at Week 348-3.5 ± 1.20-3.6 ± 1.14
Change from Core Baseline at Week 360-3.6 ± 1.21-3.4 ± 1.13
Change from Core Baseline at Week 372-3.6 ± 1.18-3.6 ± 1.26
Change from Core Baseline at Week 384-3.4 ± 1.24-3.5 ± 1.26
Change from Core Baseline at Week 396-3.5 ± 1.38-3.8 ± 1.12
Change from Core Baseline at Week 408-3.8 ± 0.97-2.8 ± 0.25
SecondaryChange From Core Baseline in Simple Disease Activity Index (SDAI): OC

SDAI score consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm), CRP (mg/dL). SDAI = TJC + SJC + SGA + PGA+ CRP. The SDAI score ranged from 0 to approximately 86. Higher SDAI indicated greater disease activity. A negative change from baseline indicated improvement.

Time frame:
Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Mean · score on a scale
Change From Core Baseline in Simple Disease Activity Index (SDAI): OC
score on a scaleFilgotinib Darwin 1Filgotinib Darwin 2
Change from Core Baseline at Extension Baseline-30.2 ± 15.49-29.8 ± 14.27
Change from Core Baseline at Week 12-33.4 ± 14.16-34.1 ± 13.79
Change from Core Baseline at Week 24-34.0 ± 14.19-35.0 ± 14.65
Change from Core Baseline at Week 36-34.7 ± 13.98-35.9 ± 13.42
Change from Core Baseline at Week 48-34.7 ± 14.38-36.2 ± 14.08
Change from Core Baseline at Week 60-35.3 ± 13.57-36.3 ± 12.85
Change from Core Baseline at Week 72-35.4 ± 13.38-36.7 ± 13.41
Change from Core Baseline at Week 84-35.6 ± 13.38-37.3 ± 13.12
Change from Core Baseline at Week 96-36.2 ± 13.31-36.8 ± 13.47
Change from Core Baseline at Week 108-36.0 ± 13.56-36.6 ± 13.65
Change from Core Baseline at Week 120-36.1 ± 13.28-37.4 ± 12.90
Change from Core Baseline at Week 132-35.6 ± 13.38-36.9 ± 14.25
Change from Core Baseline at Week 144-35.7 ± 13.15-36.9 ± 13.12
Change from Core Baseline at Week 156-35.5 ± 13.36-36.9 ± 14.46
Change from Core Baseline at Week 168-35.8 ± 14.18-36.9 ± 13.84
Change from Core Baseline at Week 180-36.2 ± 12.72-36.9 ± 13.33
Change from Core Baseline at Week 192-35.5 ± 12.74-38.2 ± 13.66
Change from Core Baseline at Week 204-35.8 ± 12.78-38.5 ± 13.72
Change from Core Baseline at Week 216-36.1 ± 12.92-38.0 ± 13.85
Change from Core Baseline at Week 228-36.8 ± 12.38-37.9 ± 12.87
Change from Core Baseline at Week 240-35.9 ± 12.69-37.1 ± 14.38
Change from Core Baseline at Week 252-37.2 ± 12.63-38.6 ± 14.85
Change from Core Baseline at Week 264-37.3 ± 12.98-39.2 ± 14.59
Change from Core Baseline at Week 276-37.5 ± 12.18-38.6 ± 13.98
Change from Core Baseline at Week 288-37.0 ± 13.22-38.6 ± 15.09
Change from Core Baseline at Week 300-37.5 ± 13.55-38.0 ± 15.38
Change from Core Baseline at Week 312-37.1 ± 13.71-37.7 ± 15.54
Change from Core Baseline at Week 324-37.7 ± 13.06-38.1 ± 15.56
Change from Core Baseline at Week 336-36.7 ± 12.52-36.6 ± 14.36
Change from Core Baseline at Week 348-37.0 ± 12.53-37.2 ± 13.02
Change from Core Baseline at Week 360-37.4 ± 12.83-36.3 ± 13.05
Change from Core Baseline at Week 372-37.3 ± 12.68-37.8 ± 13.64
Change from Core Baseline at Week 384-36.5 ± 12.64-36.5 ± 14.58
Change from Core Baseline at Week 396-36.3 ± 14.32-39.5 ± 13.50
Change from Core Baseline at Week 408-40.4 ± 12.91-35.6 ± 5.98
SecondaryChange From Core Baseline in Clinical Disease Activity Index (CDAI): OC

The CDAI was the SDAI modified that excluded CRP and consisted of following parameters: TJC (28 joints), SJC (28 joints), SGA (0 to 10 cm), PGA (0 to 10 cm). SDAI = TJC + SJC + SGA+ PGA. The CDAI score ranged from 0 to approximately 76. Higher CDAI indicated greater disease activity. A negative change from baseline indicated improvement.

Time frame:
Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Mean · score on a scale
Change From Core Baseline in Clinical Disease Activity Index (CDAI): OC
score on a scaleFilgotinib Darwin 1Filgotinib Darwin 2
Change from Core Baseline at Extension Baseline-28.8 ± 14.58-28.0 ± 13.68
Change from Core Baseline at Week 12-31.8 ± 13.45-32.4 ± 12.76
Change from Core Baseline at Week 24-32.4 ± 13.63-32.9 ± 13.79
Change from Core Baseline at Week 36-33.0 ± 13.44-33.8 ± 12.51
Change from Core Baseline at Week 48-33.1 ± 13.79-34.1 ± 13.18
Change from Core Baseline at Week 60-33.7 ± 12.97-34.2 ± 12.22
Change from Core Baseline at Week 72-33.8 ± 12.73-34.4 ± 12.57
Change from Core Baseline at Week 84-33.9 ± 12.82-35.2 ± 12.31
Change from Core Baseline at Week 96-34.6 ± 12.76-34.7 ± 12.56
Change from Core Baseline at Week 108-34.3 ± 12.96-34.5 ± 12.92
Change from Core Baseline at Week 120-34.5 ± 12.70-35.2 ± 11.87
Change from Core Baseline at Week 132-34.1 ± 12.82-34.7 ± 13.07
Change from Core Baseline at Week 144-34.1 ± 12.63-34.9 ± 12.12
Change from Core Baseline at Week 156-34.0 ± 12.74-34.8 ± 13.29
Change from Core Baseline at Week 168-34.1 ± 13.64-34.8 ± 12.55
Change from Core Baseline at Week 180-34.5 ± 12.10-34.8 ± 12.39
Change from Core Baseline at Week 192-33.9 ± 12.10-35.9 ± 12.65
Change from Core Baseline at Week 204-34.2 ± 12.26-36.3 ± 12.79
Change from Core Baseline at Week 216-34.5 ± 12.18-36.0 ± 13.00
Change from Core Baseline at Week 228-35.2 ± 11.69-35.8 ± 11.98
Change from Core Baseline at Week 240-34.3 ± 11.99-35.2 ± 13.27
Change from Core Baseline at Week 252-35.3 ± 11.94-36.4 ± 13.55
Change from Core Baseline at Week 264-35.6 ± 12.15-36.9 ± 13.53
Change from Core Baseline at Week 276-35.9 ± 11.38-36.4 ± 12.84
Change from Core Baseline at Week 288-35.4 ± 12.28-36.5 ± 13.47
Change from Core Baseline at Week 300-35.8 ± 12.84-35.7 ± 14.29
Change from Core Baseline at Week 312-35.5 ± 13.10-35.5 ± 14.40
Change from Core Baseline at Week 324-35.8 ± 12.30-36.0 ± 14.37
Change from Core Baseline at Week 336-35.0 ± 11.76-34.2 ± 13.32
Change from Core Baseline at Week 348-35.3 ± 11.70-34.8 ± 11.73
Change from Core Baseline at Week 360-35.5 ± 12.00-34.0 ± 11.54
Change from Core Baseline at Week 372-35.4 ± 12.46-33.9 ± 12.73
Change from Core Baseline at Week 384-34.8 ± 11.82-32.6 ± 13.11
Change from Core Baseline at Week 396-34.7 ± 13.28-34.2 ± 12.55
Change from Core Baseline at Week 408-39.2 ± 12.87-34.9 ± 6.36
SecondaryPercentage of Participants Achieving European League Against Rheumatism (EULAR) Response: OC

DAS28(CRP) was categorized into EULAR response categories (none, moderate, good) as follows: None= Actual DAS28(CRP) ≤ 3.2, \> 3.2 to ≤ 5.1, or \> 5.1 AND Improvement in DAS28(CRP) from baseline ≤ 6.0 or \> 0.6 to ≤ 1.2; Moderate= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline \> 0.6 to ≤ 1.2, Actual DAS28(CRP) \> 3.2 to ≤ 5.1 or \> 5.1 AND Improvement in DAS28(CRP) from baseline \> 1.2, or Actual DAS28(CRP) \> 3.2 to ≤ 5.1 AND Improvement in DAS28(CRP) from baseline \> 0.6 to ≤ 1.2; Good= Actual DAS28(CRP) ≤ 3.2 AND Improvement in DAS28(CRP) from baseline \> 1.2.

Time frame:
Core Baseline, Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving European League Against Rheumatism (EULAR) Response: OC
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline: Good46.241.5
Extension Baseline: Moderate43.648.7
Extension Baseline: None10.29.8
Week 12: Good59.160.3
Week 12: Moderate35.534.9
Week 12: None5.34.7
Week 24: Good65.265.9
Week 24: Moderate29.328.9
Week 24: None5.45.2
Week 36: Good66.466.0
Week 36: Moderate29.730.6
Week 36: None3.93.4
Week 48: Good67.768.7
Week 48: Moderate27.827.4
Week 48: None4.54.0
Week 60: Good67.864.2
Week 60: Moderate29.934.2
Week 60: None2.31.6
Week 72: Good70.565.3
Week 72: Moderate26.732.9
Week 72: None2.81.7
Week 84: Good70.369.8
Week 84: Moderate27.629.1
Week 84: None2.11.2
Week 96: Good72.969.1
Week 96: Moderate25.227.9
Week 96: None1.93.0
Week 108: Good74.266.7
Week 108: Moderate23.629.6
Week 108: None2.23.8
Week 120: Good74.667.9
Week 120: Moderate23.729.6
Week 120: None1.82.5
Week 132: Good69.169.9
Week 132: Moderate28.827.5
Week 132: None2.12.6
Week 144: Good72.365.6
Week 144: Moderate25.833.1
Week 144: None1.81.3
Week 156: Good69.064.7
Week 156: Moderate28.330.9
Week 156: None2.84.4
Week 168: Good73.468.3
Week 168: Moderate23.629.5
Week 168: None3.02.2
Week 180: Good74.068.5
Week 180: Moderate25.328.7
Week 180: None0.72.8
Week 192: Good71.271.1
Week 192: Moderate26.328.1
Week 192: None2.50.7
Week 204: Good73.376.3
Week 204: Moderate23.822.2
Week 204: None2.91.5
Week 216: Good72.769.9
Week 216: Moderate26.128.6
Week 216: None1.11.5
Week 228: Good76.470.1
Week 228: Moderate23.629.9
Week 228: None00
Week 240: Good73.263.1
Week 240: Moderate26.136.9
Week 240: None0.80
Week 252: Good74.273.4
Week 252: Moderate24.525.7
Week 252: None1.30.9
Week 264: Good74.475.5
Week 264: Moderate24.222.7
Week 264: None1.31.8
Week 276: Good74.470.2
Week 276: Moderate25.128.1
Week 276: None0.51.8
Week 288: Good73.673.0
Week 288: Moderate24.524.3
Week 288: None1.92.7
Week 300: Good74.874.5
Week 300: Moderate23.825.5
Week 300: None1.50
Week 312: Good75.866.3
Week 312: Moderate22.232.7
Week 312: None1.91.0
Week 324: Good75.771.8
Week 324: Moderate21.826.2
Week 324: None2.51.9
Week 336: Good74.271.9
Week 336: Moderate24.726.0
Week 336: None1.02.1
Week 348: Good76.978.5
Week 348: Moderate21.520.4
Week 348: None1.61.1
Week 360: Good73.373.2
Week 360: Moderate23.924.4
Week 360: None2.82.4
Week 372: Good76.877.8
Week 372: Moderate21.318.1
Week 372: None1.94.2
Week 384: Good70.378.1
Week 384: Moderate28.420.3
Week 384: None1.31.6
Week 396: Good73.281.0
Week 396: Moderate21.719.0
Week 396: None5.10
Week 408: Good100.050.0
Week 408: Moderate050.0
Week 408: None00
SecondaryPercentage of Participants Achieving ACR/EULAR Remission: NRI

A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR/EULAR Remission: NRI
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline10.17.4
Week 1213.111.6
Week 2414.915.3
Week 3615.314.5
Week 4817.714.0
Week 6015.512.4
Week 7215.512.0
Week 8415.112.4
Week 9618.311.2
Week 10814.910.7
Week 12012.313.2
Week 13212.112.8
Week 14410.59.9
Week 15610.98.3
Week 16813.97.9
Week 18010.311.2
Week 19210.110.7
Week 20411.19.5
Week 21611.57.9
Week 22811.99.9
Week 2408.97.4
Week 2527.87.9
Week 26411.37.4
Week 2768.99.5
Week 28810.19.9
Week 30010.98.7
Week 31210.57.9
Week 3249.510.3
Week 3368.57.4
Week 3489.19.1
Week 3609.36.2
Week 3728.26.6
Week 3846.64.5
Week 3967.85.4
Week 4080.40
SecondaryPercentage of Participants Achieving ACR/EULAR Remission: OC

A participant's disease activity status was defined as being in remission when scores on the TJC28, SJC28, CRP (actual value in mg/dL) and SGA (cm) were all ≤ 1.

Time frame:
Extension Baseline, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, 312, 324, 336, 348, 360, 372, 384, 396, 408
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR/EULAR Remission: OC
percentage of participantsFilgotinib Darwin 1Filgotinib Darwin 2
Extension Baseline10.17.5
Week 1213.311.9
Week 2416.617.2
Week 3617.517.0
Week 4820.716.7
Week 6019.215.9
Week 7219.716.7
Week 8419.717.3
Week 9624.016.1
Week 10820.616.1
Week 12017.920.0
Week 13217.919.7
Week 14415.815.2
Week 15618.214.4
Week 16823.113.7
Week 18017.418.8
Week 19217.418.8
Week 20419.917.0
Week 21621.214.2
Week 22822.018.6
Week 24016.814.6
Week 25216.316.8
Week 26424.216.2
Week 27620.220.0
Week 28823.321.6
Week 30026.319.6
Week 31224.818.1
Week 32422.723.8
Week 33621.318.4
Week 34823.723.4
Week 36024.916.7
Week 37224.618.8
Week 38420.012.9
Week 39625.216.3
Week 40866.70
SecondaryChange From Core Baseline in Physical Component Score (PCS) of Quality of Life Using the Short Form-36 (SF-36) Scores: OC

The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components: * Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items). * Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items). These scales were from 0 to 100 with higher scores indicating a better quality of life.

Time frame:
Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Reported as:
Mean · score on a scale
Change From Core Baseline in Physical Component Score (PCS) of Quality of Life Using the Short Form-36 (SF-36) Scores: OC
score on a scaleFilgotinib Darwin 1Filgotinib Darwin 2
Change from Core Baseline at Extension Baseline9.2 ± 9.119.5 ± 8.85
Change from Core Baseline at Week 4811.3 ± 9.4511.5 ± 8.74
Change from Core Baseline at Week 9612.2 ± 9.7011.8 ± 8.87
Change from Core Baseline at Week 14411.8 ± 9.8612.2 ± 9.21
Change from Core Baseline at Week 19211.2 ± 9.2111.0 ± 9.40
Change from Core Baseline at Week 24010.9 ± 9.5811.4 ± 9.29
Change from Core Baseline at Week 28813.0 ± 10.7113.1 ± 9.50
Change from Core Baseline at Week 33612.8 ± 10.1212.0 ± 8.79
Change from Core Baseline at Week 38411.5 ± 9.9711.7 ± 8.00
SecondaryChange From Core Baseline in MCS of Quality of Life Using the SF-36 Scores: OC

The health-related quality of life of the subject was assessed using the SF-36 with a 4-week recall period. This consists of 36 questions belonging to 8 domains in 2 components: * Physical well-being: 4 domains: physical functioning (10 items), role physical (4 items), bodily pain (2 items), and general health (GH) perceptions (5 items). * Mental well-being: 4 domains: vitality (4 items), social functioning (2 items), role emotional (3 items), and mental health (5 items). These scales were from 0 to 100 with higher scores indicating a better quality of life.

Time frame:
Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Reported as:
Mean · score on a scale
Change From Core Baseline in MCS of Quality of Life Using the SF-36 Scores: OC
score on a scaleFilgotinib Darwin 1Filgotinib Darwin 2
Change from Core Baseline at Extension Baseline6.1 ± 9.677.1 ± 10.01
Change from Core Baseline at Week 486.2 ± 10.526.8 ± 10.84
Change from Core Baseline at Week 966.5 ± 10.546.7 ± 10.33
Change from Core Baseline at Week 1446.2 ± 10.726.6 ± 10.86
Change from Core Baseline at Week 1926.1 ± 11.477.5 ± 11.60
Change from Core Baseline at Week 2406.5 ± 11.117.7 ± 11.66
Change from Core Baseline at Week 2887.3 ± 11.498.2 ± 11.20
Change from Core Baseline at Week 3366.7 ± 10.496.6 ± 13.65
Change from Core Baseline at Week 3846.3 ± 11.238.0 ± 10.98
SecondaryChange From Core Baseline in Quality of Life Using Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale: OC

FACIT-Fatigue scale was a 13-item questionnaire, each scored on a 5-point scale: 0 (Not at all) to 4 (Very much). Negatively stated items were reversed by subtracting the response from "4" before being added to obtain a total score. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score), with a higher score indicating less fatigue. A positive change from baseline indicated better quality of life.

Time frame:
Core Baseline, Extension Baseline, Weeks 48, 96, 144, 192, 240, 288, 336, 384
Reported as:
Mean · score on a scale
Change From Core Baseline in Quality of Life Using Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale: OC
score on a scaleFilgotinib Darwin 1Filgotinib Darwin 2
Change from Core Baseline at Extension Baseline10.7 ± 11.0612.1 ± 10.71
Change from Core Baseline at Week 4811.6 ± 11.1612.7 ± 11.62
Change from Core Baseline at Week 9612.0 ± 11.5912.9 ± 10.97
Change from Core Baseline at Week 14412.3 ± 11.3113.2 ± 11.92
Change from Core Baseline at Week 19211.7 ± 11.6312.8 ± 11.96
Change from Core Baseline at Week 24011.5 ± 11.5212.5 ± 11.74
Change from Core Baseline at Week 28813.4 ± 13.2115.0 ± 12.03
Change from Core Baseline at Week 33613.2 ± 12.1813.8 ± 12.29
Change from Core Baseline at Week 38412.6 ± 13.3513.9 ± 10.76

Adverse events

Collected over From First dose to Week 437. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib Darwin 18/497 (1.6%)84/497 (16.9%)386/497 (77.7%)
Filgotinib Darwin 28/242 (3.3%)48/242 (19.8%)189/242 (78.1%)
Most frequent serious events
Showing 10 of 145
Most frequent serious events
EventFilgotinib Darwin 1Filgotinib Darwin 2
OsteoarthritisMusculoskeletal and connective tissue disorders7/4973/242
PneumoniaInfections and infestations7/4973/242
Non-Hodgkin's lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4973/242
COVID-19 pneumoniaInfections and infestations6/4972/242
CholelithiasisHepatobiliary disorders5/4971/242
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4972/242
Femur fractureInjury, poisoning and procedural complications3/4972/242
Humerus fractureInjury, poisoning and procedural complications0/4972/242
Acute kidney injuryRenal and urinary disorders0/4972/242
Urinary tract infectionInfections and infestations0/4972/242
Most frequent other events
Showing 10 of 22
Most frequent other events
EventFilgotinib Darwin 1Filgotinib Darwin 2
Mycobacterium tuberculosis complex test positiveInvestigations58/49740/242
Upper respiratory tract infectionInfections and infestations57/49737/242
HypertensionVascular disorders75/49727/242
Urinary tract infectionInfections and infestations72/49730/242
NasopharyngitisInfections and infestations70/49724/242
HypercholesterolaemiaMetabolism and nutrition disorders39/49730/242
BronchitisInfections and infestations59/49719/242
HeadacheNervous system disorders34/49726/242
Blood cholesterol increasedInvestigations13/49723/242
LymphopeniaBlood and lymphatic system disorders45/49723/242

Baseline characteristics

The Safety Analysis Set included all participants who enrolled in the extension study and received at least one dose of study drug. As prespecified in the protocol, data was collected and analyzed based on their originating parent study I.e. DARWIN 1 and DARWIN 2.

Age, Continuous
Age, Continuous(years)Filgotinib Darwin 1Filgotinib Darwin 2Total
Mean53 ± 11.752 ± 12.253 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Filgotinib Darwin 1Filgotinib Darwin 2Total
Female405198603
Male9244136
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Filgotinib Darwin 1Filgotinib Darwin 2Total
Hispanic or Latino20885293
Not Hispanic or Latino289157446
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Filgotinib Darwin 1Filgotinib Darwin 2Total
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander011
Black or African American336
White374181555
More than one race000
Unknown or Not Reported11956175
08

Study locations

111 sites
  • Arthro, Arthritis Care & Research
    Gilbert, Arizona, United States
  • Arizona Arthritis & Rheumatology Research PLLC
    Mesa, Arizona, United States
  • C.V. Mehta MD Medical Corp.
    Hemet, California, United States
  • Desert Medical Advances
    Palm Desert, California, United States
  • RASF Clinical Research Center
    Boca Raton, Florida, United States
  • Millenium Research
    Ormond Beach, Florida, United States
  • Lovelace Scientific Resources
    Venice, Florida, United States
  • Springfield Clinic
    Springfield, Illinois, United States
  • Klein and Associates MD, PA
    Hagerstown, Maryland, United States
  • Physicians East
    Greenville, North Carolina, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma, United States
  • Low County Rheumatology PA
    Charleston, South Carolina, United States
  • West Tennessee Research Institute
    Jackson, Tennessee, United States
  • Austin Rheumatology Research PA
    Austin, Texas, United States
  • Pioneer Research Solutions Inc
    Houston, Texas, United States
  • Atencion Integral en Reumatologa
    Buenos Aires, Argentina
  • CER Intituto Medico
    Buenos Aires, Argentina
  • Organizacion Medica de Investigaciones (OMI)
    Buenos Aires, Argentina
  • Instituto Reumatologico Strusberg
    Cordoba, Argentina
  • CIMeL Centro dee Investigacion Medico Lanus
    Lanus, Argentina
  • Instituto CAICI
    Rosario, Argentina
  • Instituto de Asistencia Reumatologia Integral - IARI
    San Fernando, Argentina
  • Centro Médico Privado de Reumatologia
    San Miguel de Tucumán, Argentina
  • Flinders Medical Centre
    Bedford Park, Flinders Drive, South Australia, Australia
  • Monash Medical Centre
    Clayton, Victoria, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Australia
  • Cliniques Universitaires St-Luc
    Brussels, Belgium
  • UZ Leuven
    Leuven, Belgium
  • University "Multiprofile Hospital for Active Treatment - Kaspela" LTD
    Plovdiv, Bulgaria
  • Multiprofile Hospital for Active Treatment - Ruse
    Ruse, Bulgaria
  • Diagnostic Consultative Center "Sveta Anna" LTD
    Sofia, Bulgaria
  • National Multiprofile Transport Hospital "Tsar Boris III," Sofia, Clinical of Internal Diseases
    Sofia, Bulgaria
  • University Multiprofile Hospital for Active Treatment "SV. Ivan Rilski" EAD, Sofia, Rheumatology Clinic
    Sofia, Bulgaria
  • Hospital Regional "Guillermo Grant Benavente"
    Santiago, Chile
  • Prosalud
    Santiago, Chile
  • Someal SA
    Santiago, Chile
  • Centro de Investigacion Clinica del Sur
    Temuco, Chile
  • Consulta Privada Dra. Ponce
    Temuco, Chile
  • Medicity S.A.S.
    Bucaramanga, Santander, Colombia
  • Circaribe S.A.S
    Barranquilla, Colombia
  • Centro de Investigacion en Reumatologia y Especialidades Medicas (CIREEM)
    Bogota, 110221, Colombia
  • Idearg Sas
    Bogota, Colombia
  • Riesgo De Fractura Cayre Ips7
    Bogotá, 110221, Colombia
  • Preventive Care SAS
    Cundinamarca, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, Colombia
  • Revmatologie S.R.O
    Brno, Czechia
  • Revmatologicka a interni ambulance
    Kladno, Czechia
  • Revmatologicka ambulance
    Praha-Nusle, Czechia
  • PV-Medical S.R.O.
    Zlin, Czechia
  • Hospitaux de Hautepierre
    Strasbourg CEDEX, France
  • Schlossparkklinik - Akad. Lehrkrankenhaus Charite
    Berlin, Germany
  • MVZ Rheumatologie and Autoimmun Medizin HH GmbH
    Hamburg, Germany
  • Centro Clinico
    Guatemala City, Guatemala
  • Clinica de Especialidades Medicas
    Guatemala, Guatemala
  • Clinica Medica Especializada en Reumatologia
    Guatemala, Guatemala
  • Clinica Medica
    Guatemala, Guatemala
  • Reuma S.A.
    Guatemala, Guatemala
  • Reuma-Centro
    Guatemala, Guatemala
  • Gyogyszervizs galo Kozpont Kft
    Balatonfured, Hungary
  • QualiClinic Kft.
    Budapest, Hungary
  • Reumatologiai Kft.
    Budapest, Hungary
  • Markhot Ferenc Hospital, Rheumatology
    Eger, Hungary
  • Csolnoky Ferenc Hospital, Rheumatology
    Veszprem, Hungary
  • Carmel Medical Center
    Haifa, Israel
  • Rambam Medical Center
    Haifa, Israel
  • Ltd M&M Centr
    Adazi, Latvia
  • SIA Arijas Ancane's Family Doctor
    Baldone, Latvia
  • Daugavpils Regional Hospital
    Daugavpils, Latvia
  • L. Atikes doktorats
    Liepaja, Latvia
  • 'Bruninieku' polyclinic
    Riga, Latvia
  • Centro Medico Dalinde
    Ciudad de Mexico, Mexico
  • Centro de Estudios de Investigacion Basica y Clinica, SC
    Guadalajara, Mexico
  • Arke Estudios Clinicos S.A. de C.V.
    Mexico, Mexico
  • Clinstile, S.A. de C.V.
    Mexico, Mexico
  • Hospital General de México
    Mexico, Mexico
  • Hospital Universitario José E. Gonzalez
    Monterrey, Mexico
  • OSMO
    Oaxaca, Mexico
  • IMSP Institutul de Cardiologie
    Chisinau, Moldova, Republic of
  • Waikato Hospital
    Hamilton, New Zealand
  • Timaru Rheumatology Studies
    Timaru, New Zealand
  • NZOZ Osteo-Medic s.c.
    Bialystok, Poland
  • Centrum Medyczne Silesiana Sp. Z.o.o.
    Bytom, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, Poland
  • Centrum Medyczne Plejady
    Krakow, Poland
  • NZOZ "DOBRY LEKARZ" Specjalistyczne Poradnie Lekarskie
    Krakow, Poland
  • Specjalistyczne Centrum Medyczne Nowomed
    Krakow, Poland
  • NZOZ Przychodnia Lekarska "Eskulap"
    Skierniewice, Poland
  • Powiatowy Zaklad Opieki Zdrowotnej w Starachowicach
    Starachowice, Poland
  • NZOZ "Nasz Lekarz" Pratyka Grupowa Lekarzy Rodzinnychz
    Torun, Poland
  • AMED Medical Center
    Warsaw, Poland
  • Rheumatica Sp. Z.o.o.
    Warszawa, Poland
  • Spitalul Clinic Sfanta Maria
    Bucuresti, Romania
  • Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Galati
    Galati, Romania
  • First Moscow State Medical University n.a. I.M. Sechenova of the Ministry of Health
    Moscow, Russian Federation
  • Scientific Research Institute of Rheumatology
    Moscow, Russian Federation
  • City Clinical Hospital #5
    Nizhniy Novgorod, Russian Federation
  • GBOU VPO Orenburg State Medical University
    Orenburg, Russian Federation
  • Ryazan State Medical University
    Ryazan, Russian Federation
  • Regional Clinical Hospital
    Saratov, Russian Federation
  • City Hospital #26
    St Petersburg, Russian Federation

Showing the first 100 of 111 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Genovese MC, Kavanaugh A, Winthrop K, et al. Long Term Safety of Filgotinib in the Treatment of Rheumatoid Arthritis: Week 84 Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10).
  • Kavanaugh A, Westhovens R, Winthrop K, et al. Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
  • R. Westhovens, R. Alten, K. Winthrop, et al. Long term safety of filgotinib in the treatment of rheumatoid arthritis: week 108 data from a phase 2b open-label extension study. [abstract]. Ann Rheum Dis. 2018;77 (suppl 2)
  • Kavanaugh A, Genovese MC, Winthrop K, et al. Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9).
  • Kavanaugh A, Westhovens RR, Winthrop KL, Lee SJ, Tan Y, An D, Ye L, Sundy JS, Besuyen R, Meuleners L, Stanislavchuk M, Spindler AJ, Greenwald M, Alten R, Genovese MC. Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. J Rheumatol. 2021 Aug;48(8):1230-1238. doi: 10.3899/jrheum.201183. Epub 2021 Feb 1. PubMed 33526618 ↗
  • Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7. PubMed 36205910 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for clinical trials that support an approved indication in the EU and the US for which Galapagos is the Marketing Authorisation / New Drug Application Holder, with a marketing authorisation date on or after January 1, 2021 and for which the summary results have been published on ClinicalTrials.gov (CT.gov) and/or the EU Clinical Trials Register (EU CTR). For clinical trials of newly approved compounds or indications the IPD can be requested at earliest 6 months after the EMA and FDA approval. The study last patient last visit (LPLV) must have occurred at least 18 months prior to the request.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Jan 2023, 106 months.

Results were first posted in Jun 2024, 1 year 4 months after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 106 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Feb 19, 2014
StartActual
Feb 25, 2014
Primary completionActual
Jan 19, 2023
CompletionActual
Jan 19, 2023
Results first posted
Jun 4, 2024
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02065700
Lead sponsor
Galapagos NV
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Feb 19, 2014
Start date
Feb 25, 2014
Primary completion
Jan 19, 2023
Completion
Jan 19, 2023
Results posted
Jun 4, 2024
Last update
Jun 4, 2024

Study contacts

Galapagos Study Director
study director · Galapagos NV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion